DURHAM, N.C.--An ever-growing world population, coupled with increasing
feed costs and production pressures, will make demands on the global
poultry industry greater than ever in years ahead.
Poised to meet those demands is the Poultry Health Division of Pfizer
Animal Health (PPH), a hybrid of engineering and poultry animal health
technology and innovation that was born via the acquisition of Embrex,
Inc. by Pfizer Animal Health in 2007.
“The extensive poultry production knowledge; network of scientists and
engineers that Embrex brought to the organization, coupled with Pfizer’s
existing veterinary medicine research and development organization, is
allowing our new organization to unlock the potential for developing and
marketing new technologies to enhance global poultry production,” says
Kirk Adams, Group Director, Global Marketing, New Business Marketing,
and Strategic Planning.
Future In Ovo Innovations
The Embrex® Inovoject® System, a flagship product developed by Embrex,
delivers vaccines via sterile injection in ovo, before chicks
even are hatched. Inovoject, which can inject up to 60,000 eggs per
hour, has been used widely throughout the world to administer vaccines.
“The efficiency and precision of in ovo,vaccine delivery has
become a management breakthrough in the global poultry industry,” says
Adams. “Based on customer demand, we currently are refining the process
further by researching a gender-sorting feature for Inovoject.”
Biologicals
Developing new vaccines labeled for in ovo,administration is
another key priority for PPH. “In the future, we plan to supply the
industry with more biological products developed to initiate disease
prevention and control via in ovo,administration. The labor
savings and more consistent delivery and protection provided by such
products will help to further drive progress in global poultry
production enterprises,” says Greg Pruitt, Associate Director, Pfizer
Poultry Health R&D.
Of particularly high importance is addressing coccidiosis, one of the
most prevalent and costly poultry diseases worldwide. “Reformulated
coccidiosis-prevention products that are stable for longer periods of
time are needed to gain more thorough and consistent control of this
costly disease,” says Pruitt. “An intense focus on coccidiosis is
currently one of our highest research and development priorities.”
Bird Performance
Of particularly high importance is addressing coccidiosis, one of the
most prevalent and costly poultry diseases worldwide. “Reformulated
coccidiosis-prevention products that are stable for longer periods of
time are needed to gain more thorough and consistent control of this
costly disease,” says Pruitt. “An intense focus on coccidiosis is
currently one of our highest research and development priorities.”
“We serve an industry that supplies the world with one of the most
nutritious and affordable sources of protein available,” says Pruitt.
“We know that the global poultry industry will face challenges in the
future -- in terms of disease, feed costs, labor availability, and the
need to be highly efficient to be profitable. The Poultry Health
Division of Pfizer Animal Health will do all that it can to help our
customers meet those challenges.”
The Poultry Health Division of Pfizer Animal Health is a leading
provider of innovative, high-performance poultry health solutions to the
global poultry industry. Built upon the combined strength and experience
of Embrex and Pfizer Animal Health, the Pfizer Poultry Health is
committed to developing and marketing commercially novel vaccines and
mechanical and data management products which continue to provide
increasing value to the global poultry health industry. For more
information about the Pfizer Poultry Health, visit us online at www.pfizerpoultryhealth.com.
For More Information:
Melinda Freson
Pfizer Poultry Health
919-314-2698
melinda.freson@pfizer.com
or
Jill Spiekerman-Carrothers
MartinWilliams
515-971-9613
j.spiekerman@martinwilliams.com